Back to search results

A Study of LAD603 for Alopecia Areata

This study is looking at a new treatment called LAD603 for adults with severe to very severe alopecia areata (AA), a condition where the immune system attacks hair follicles, causing hair loss. Researchers want to see how well LAD603 works to regrow hair and if it is safe. You would receive either LAD603 or a placebo (an inactive substance that looks like the study drug) through injections under the skin. The main way success will be measured is by looking at changes in your hair loss using a tool called the Severity of Alopecia Tool (SALT) score over 28 weeks. The study aims to enroll 136 participants and its current status is unclear.

Study design
This interventional study plans to enroll 136 participants. It compares LAD603 administered subcutaneously to a matching placebo, also given subcutaneously.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at Week 28.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07311564

A Study of LAD603 in Adults With Alopecia Areata

Recruiting
PHASE2Ages 18–65InterventionalTreatment
Almirall, S.A.
~136 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:LAD603Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Change from Baseline in the Severity of Alopecia Tool (SALT) Score
Measured over Baseline, Week 28

Conditions

Alopecia Areata

Explore related trials

Alopecia

Where it's being run

1 sites across 1 states
Nebraska1

Study leadership

  • Study Director · STUDY_DIRECTOR · Almirall, S.A.

Who to contact

Davide Carluccio
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant is a male or female between 18 and 65 years old at the time of signing the informed consent.
Severe to very severe AA criteria:
Participants who are WOCBP or male must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD603 during the study,

Exclusion

Participants have other types of alopecia (including but not limited to traction, scarring alopecia).
Participants with "diffuse" type AA.
Currently has an active form of other inflammatory skin disease(s) or evidence of skin condition (e.g., psoriasis, seborrheic dermatitis, lupus) at the time of the Screening or Baseline (Day 1) visits that is expected to interfere with the assessment of alopecia areata severity.
Participant has previous severe adverse reaction to subcutaneously administered medication.
Participant has any of the following liver safety laboratory results at Screening
Intention to use any concomitant medication that is not permitted by this protocol or failure to undergo the required washout period for a particular prohibited medication.

What this trial measures

  • Percent Change from Baseline in the Severity of Alopecia Tool (SALT) ScoreBaseline, Week 28

    The SALT score is the sum of percentage of hair loss in all areas with a maximum score of 100 (higher score indicates greater hair loss).